Special Issue "Research Advances and Therapeutic Strategies of Human Osteosarcoma"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 15 July 2020.

Special Issue Editors

Dr. Frédéric Lézot
Website
Guest Editor
INSERM, UMR-1238, Laboratory Bone Sarcoma and Remodeling of Calcified tissues, Team Microenvironment of Primary Bone Tumors: signaling and therapeutic targeting, Faculty of Medicine, Université de Nantes, Nantes F-44035, France
Interests: primary bone tumors; RANKL/RANK/OPG signaling; tumor microenvironment; metastases; drug resistance; therapies
Dr. Bénédicte Brounais-Le-Royer
Website
Guest Editor
INSERM, UMR-1238, Laboratory Bone Sarcoma and Remodeling of Calcified tissues, Team Microenvironment of Primary Bone Tumors: signaling and therapeutic targeting, Faculty of Medicine, Université de Nantes, Nantes F-44035, France
Interests: bone sarcoma; Wnt signaling; metastases; tumor microenvironment
Prof. Dr. Dominique Heymann
Website
Guest Editor
INSERM, UMR 1232, Institut de Cancérologie de l’Ouest, Université de Nantes, Bd Jacques Monod, 44805, Saint-Herblain, France
Interests: sarcoma; circulating tumor cells; dormancy; drug resistance; microenvironment; microfluidics

Special Issue Information

Dear Colleagues,

Osteosarcoma is the most frequent pediatric primary bone tumor. Current treatments that combine conventional chemotherapies and surgery have enabled to reach a five-year remission rate higher than 70%. However, this rate dramatically decreases below 30% if metastases are observed at the time of diagnosis or if the tumor is resistant to chemotherapy. In the last decade, besides researches on new therapeutic targets to eradicate the tumor cells (epigenetic, genetic, or metabolic targets), many studies have been devoted to a better understanding of both metastatic and resistance processes in order to be able, in a near future, to block or reverse them. These studies have mainly focused on the tumor microenvironment and on tumor cell heterogeneity in those two processes.

This Special Issue will discuss recent developments in our understanding of osteosarcoma metastatic and resistance processes and delineate future therapies based on the blockage of these two deleterious processes.

Dr. Frédéric Lézot
Dr. Bénédicte Brounais-Le-Royer
Prof. Dominique Heymann
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • osteosarcoma
  • metastases
  • resistance
  • treatments

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
Cancers 2020, 12(4), 793; https://doi.org/10.3390/cancers12040793 - 26 Mar 2020
Abstract
Osteosarcoma (OS) is the second most common cause of cancer-related death in pediatric patients. The insulin-like growth factor (IGF) pathway plays a relevant role in the biology of OS but no IGF targeted therapies have been successful as monotherapy so far. Here, we [...] Read more.
Osteosarcoma (OS) is the second most common cause of cancer-related death in pediatric patients. The insulin-like growth factor (IGF) pathway plays a relevant role in the biology of OS but no IGF targeted therapies have been successful as monotherapy so far. Here, we tested the effect of three IGF specific inhibitors and tested ceritinib as an off-target inhibitor, alone or in combination with dasatinib, on the proliferation of seven primary OS cells. Picropodophyllin, particularly in combination with dasatinib and the combination ceritinib/dasatinib were effective in abrogating the proliferation. The ceritinib/dasatinib combination was applied to the primary cells of a 16-year-old girl with a long history of lung metastases, and was more effective than cabozantinib and olaparib. Therefore, the combination was used to treat the patient. The treatment was well tolerated, with toxicity limited to skin rush and diarrhea. A histopathological evaluation of the tumor after three months of therapy indicated regions of high necrosis and extensive infiltration of macrophages. The extension of the necrosis was proportional to the concentration of dasatinib and ceritinib in the area, as analysed by an ultra performance liquid chromatography–tandem mass spectrometer (UPLC-MS/MS). After the cessation of the therapy, radiological analysis indicated a massive growth of the patient’s liver metastases. In conclusion, these data indicate that the combination of ceritinib/dasatinib is safe and may be used to develop new therapy protocols. Full article
(This article belongs to the Special Issue Research Advances and Therapeutic Strategies of Human Osteosarcoma)
Show Figures

Figure 1

Back to TopTop